Reduced miR-142-3p levels, as Wang et al. demonstrated among AML patients, can therefore contribute to APL development by relieving its inhibition of CCNT2 and TAB2 targets [36,207]. This evidence concerns the gene CCNT2 and acute promyelocytic leukemia.